InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,306.04
(
0.02%
)
US TECH 100
18,387.60
(
0.38%
)
Dow Jones
38,852.86
(
-0.55%
)
Brent Oil
84.24
(
-0.11%
)
Bitcoin
68,455.63
(
0.24%
)
Post# of 251952
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119702
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 233970

Wednesday, 10/28/2020 4:24:52 PM

Wednesday, October 28, 2020 4:24:52 PM

Post# of 251952
GILD 3Q20 HCV sales=$464M, +4% QoQ, -31% YoY. The 3Q20 geographic breakdown was: US $241M; EU $98M; RoW $125M.

During 3Q20, COVID-19 continued to impede new-patient starts for HCV treatment in all geographies (CC slide #52, see link below). GILD’s worldwide HCV patient starts in 3Q20 (CC slide #21, see link below) were 31K, up from 25K in 2Q20, but down from 45K in 1Q20 (pre-pandemic). 21K of the 31K patient starts in 3Q20 were in the US.

PR:
https://www.gilead.com/news-and-press/press-room/press-releases/2020/10/gilead-sciences-announces-third-quarter-2020-financial-results

CC slides:
http://investors.gilead.com/static-files/7db4987f-930d-4b18-877e-0c75d5e34c0d

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up